Identification of cancer-derived peptides as potential candidates for the development of anti-cancer vaccines for prostate cancer patients

Abstract

研究代表者publisher研究種目：基盤研究（C）; 研究期間：2012～2014; 課題番号：24592416; 研究分野：泌尿器科学 科研費の分科・細目：研究成果の概要（和文): 現在, 癌ワクチン療法の多くはHLA-A3 supertype alleles陽性症例に対する適応はない. 今回, 癌ワクチン療法適応拡大のためにHLA-A3 supertype alleles陽性前立腺癌患者に対し癌ワクチン療法に応用し得るEZH2由来ペプチドの同定を試みた. HLA-A3 supertype alleles親和性より5種類のEZH2由来ペプチドを準備し免疫学的アッセイを施行した. 結果, EZH2733-741ペプチドが最もペプチド特異的細胞障害性Tリンパ球を誘導し, 癌ワクチン療法に応用しうるペプチドであることが示された. 研究成果の概要（英文）: EZH2-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Five EZH2-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11,-A31, and -A33) were screened for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype+ prostate cancer patients. As a result, EZH2733-741 efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8+ T cells. These results indicate that the EZH2733-741 peptide could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype+ prostate cancer patients